Anti-interleukin-2 receptor monoclonal antibody therapy in rats: comparison of the effector mechanisms mediated by variant murine isotypes.
Stünkel
K G
KG
Institute of Immunology and Oncology, Bayer AG, Wuppertal, West Germany.
Grützmann
R
R
Diamantstein
T
T
Kupiec-Weglinski
J W
JW
Schlumberger
H D
HD
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D002478:Cells, Cultured; D005260:Female; D014644:Genetic Variation; D007132:Immunoglobulin Isotypes / Q000276:immunology*; D007165:Immunosuppression Therapy; D007376:Interleukin-2 / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D011919:Rats, Inbred Strains; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D007132:Immunoglobulin Isotypes; D007376:Interleukin-2; D015375:Receptors, Interleukin-2